Silva Paolo S, Cavallerano Jerry D, Aiello Lloyd M
Curr Diab Rep. 2009 Aug;9(4):265-71. doi: 10.1007/s11892-009-0041-6.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus and a leading cause of new-onset vision loss in adults worldwide. Current medical and surgical evidence-based care, including laser photocoagulation, is effective in preserving vision. This care is most effective prior to the onset of ocular or visual symptoms, but many diabetic persons do not receive the recommended annual eye examination for the evaluation of the retina for level of DR. With diabetes incidence and prevalence increasing at epidemic rates and the prediction that 370 million people worldwide will have diabetes by the year 2030, human and fiscal resources will be unable to meet the visual needs with current acute care methods. Appropriate and validated telemedicine programs for DR hold the promise of both enrolling patients into appropriate eye care programs and, more importantly, providing more effective, high-quality diabetes eye care based on current and developing technology.
糖尿病视网膜病变（DR）是糖尿病的常见并发症，也是全球成年人新发视力丧失的主要原因。包括激光光凝术在内的当前基于医学和外科证据的治疗方法，在保护视力方面是有效的。这种治疗在眼部或视觉症状出现之前最为有效，但许多糖尿病患者没有接受推荐的年度眼部检查以评估视网膜的糖尿病视网膜病变水平。随着糖尿病发病率和患病率以流行率上升，且预计到2030年全球将有3.7亿人患有糖尿病，人力和财政资源将无法通过当前的急性护理方法满足视觉需求。适用于糖尿病视网膜病变的经过验证的远程医疗项目有望将患者纳入适当的眼部护理项目，更重要的是，基于当前和不断发展的技术提供更有效、高质量的糖尿病眼部护理。
